Oral tablet for non-segmental vitiligo repigmentation
Part of Skin clinical trials.
This trial tests an oral medication (a tablet) for treating non-segmental vitiligo, a condition where white patches appear on the skin. The goal is to see if the drug can safely help bring color back to those patches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosis of non-segmental vitiligo (patches on both sides of the body).
- Your vitiligo must cover a certain area: at least a small spot on your face (F-VASI score 0.5 or higher) and a larger total area (T-VASI score 3 or higher).
- Your vitiligo can be stable or spreading—both are okay.
- Less than one-third of your vitiligo patches can have white hair in them.
- You must not have other skin conditions that cause lightening or depigmentation, like tinea versicolor or post-inflammatory hypopigmentation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This trial tests a cream (ruxolitinib) combined with corticosteroid treatment for people with active, non-segmental vitiligo that affects the face. It aims to see how well this combination works in real-world settings.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
This study tests a new medication called FXS5626 to help treat non-segmental vitiligo (a type of vitiligo that affects both sides of the body). It is for people who have moderate to large patches of vitiligo, especially on the face.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
Hear when a new Non-Segmental Vitiligo (NSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.